News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProFibrix US Phase II Study with FibrocapsTM Meets All Primary and Secondary Endpoints



1/5/2012 6:16:37 AM

LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)--ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant reduction in mean time to hemostasis (TTH) and incidence of hemostasis at 3, 5 and 10 minutes, as compared to active control.

Read at BioSpace.com


comments powered by Disqus
ProFibrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES